Stem cell transplant for lymphoma at high risk of brain relapse
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This trial tests a stem cell transplant with a special chemo combination (TEAM) to see if it can prevent lymphoma from coming back in the brain or spinal cord for people with high-risk non-Hodgkin lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma (non-Hodgkin) that is at high risk of spreading to the brain or spinal cord.
- Your lymphoma got much better (complete or partial response) after your first treatment.
- You are between 18 and 70 years old.
- Your organs (like kidneys, liver, lungs, heart, and blood cells) are working well enough for a stem cell transplant.
- You are not pregnant, breastfeeding, or planning to become pregnant, and you are willing to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (cidabenamine and azacitidine) to help prevent peripheral T-cell lymphoma from coming back after a donor stem cell transplant. It is for patients who are at high risk of progression and have already had a transplant.
This trial tests a new approach that combines radiation therapy, a stem cell transplant, and a special immune cell treatment (CAR-T) for people with an aggressive type of B-cell lymphoma that has returned or stopped responding to standard treatments. The goal is to see if this powerful combination can help control the cancer better.
This trial tests if high doses of chemotherapy (thiotepa and carmustine) followed by a stem cell transplant from your own cells can prevent lymphoma from coming back in the brain or spinal cord. It's for people with aggressive lymphoma that has a higher risk of spreading to the central nervous system.
This trial tests a combination of high-dose chemotherapy drugs (gemcitabine, busulfan, and thiotepa) followed by a stem cell transplant for people with primary central nervous system lymphoma. It aims to see if this treatment can improve outcomes for patients whose disease has responded to initial therapy.
This Phase 2 trial studies methotrexate, tafasitamab, lenalidomide, and rituximab for primary B-cell lymphoma that starts in the brain/spinal fluid. It aims to see how well this combination works for people who cannot have certain high-dose stem cell treatment.
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
Hear when a new Lymphoma Patients With High-risk of Central Nervous System Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.